Zobrazeno 1 - 10
of 33
pro vyhledávání: '"William T. Duggan"'
Autor:
Nicolle M. Gatto, Michael B. Bracken, Francesca Kolitsopoulos, William T. Duggan, Gary G. Koch, Robert A. Wise, Neville C. Jackson
Publikováno v:
Contemporary Clinical Trials Communications, Vol 18, Iss , Pp 100427- (2020)
Objective: VOLUME is a randomized, open-label, post-approval pragmatic trial aiming to evaluate long-term pulmonary and cardiovascular safety of Exubera® (EXU; insulin human [rDNA origin] Inhalation Powder) in routine clinical practice. The primary
Externí odkaz:
https://doaj.org/article/e4aa5d4f7218450fa8223f858d591933
Autor:
Philip J. Barter, Kerry-Anne Rye, Mohan S. Beltangady, William C. Ports, William T. Duggan, S. Matthijs Boekholdt, David A. DeMicco, John J.P. Kastelein, Charles L. Shear
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 11, Pp 2436-2442 (2012)
Development of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, was halted after the ILLUMINATE trial revealed an increase in both all-cause mortality (ACM) and major cardiovascular events (MCVEs) associated with its use. We now
Externí odkaz:
https://doaj.org/article/189e656ae8a649159ae60d68943931b9
Autor:
Howard I. Scher, William T. Duggan, Johann S. de Bono, Andrew J. Armstrong, Cora N. Sternberg, Mary-Ellen Taplin, Kim N. Chi, Fred Saad, Karim Fizazi, Jimmy L. Zhao
Purpose:The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We investigated the association of CCU with overall survival (OS), radiograph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ca114c2cf517cbe1559e144ed24d34
https://doi.org/10.1158/1078-0432.c.6531342.v1
https://doi.org/10.1158/1078-0432.c.6531342.v1
Autor:
Howard I. Scher, William T. Duggan, Johann S. de Bono, Andrew J. Armstrong, Cora N. Sternberg, Mary-Ellen Taplin, Kim N. Chi, Fred Saad, Karim Fizazi, Jimmy L. Zhao
Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b1315295c5361403adb1c057b079ef
https://doi.org/10.1158/1078-0432.22484148.v1
https://doi.org/10.1158/1078-0432.22484148.v1
Autor:
Howard I. Scher, William T. Duggan, Johann S. de Bono, Andrew J. Armstrong, Cora N. Sternberg, Mary-Ellen Taplin, Kim N. Chi, Fred Saad, Karim Fizazi, Jimmy L. Zhao
Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ba4fbf6179daf5971a52e48a90211d
https://doi.org/10.1158/1078-0432.22484151.v1
https://doi.org/10.1158/1078-0432.22484151.v1
Autor:
Jimmy L. Zhao, Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg, Andrew J. Armstrong, Johann S. de Bono, William T. Duggan, Howard I. Scher
Publikováno v:
Clinical Cancer Research. 28:860-869
Purpose: The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We investigated the association of CCU with overall survival (OS), radiograp
Autor:
Mahgull Nazar Thakur, Toni K. Choueiri, Michael B. Atkins, David F. McDermott, Igor Puzanov, Jamal Tarazi, Ulka N. Vaishampayan, Kathrine C. Fernandez, Saby George, William T. Duggan, Daniel C. Cho, Rodolfo F. Perini, Elizabeth R. Plimack, Mayer Fishman
Publikováno v:
European Journal of Cancer. 145:1-10
Background Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a randomised phase III trial in patients with advanced renal-cell carcinoma (RCC). We
Autor:
Robert Jeraj, Alison Roth, William T. Duggan, Scott B. Perlman, Anna Ferrari, Joshua M. Lang, Jamie M. Sperger, Glenn Liu, Timothy Perk, Katharina Modelska, Anthony R. Porcari, Christos Kyriakopoulos, Elisabeth I. Heath, Anupama Singh
Publikováno v:
Journal of Clinical Oncology. 38:3662-3671
PURPOSE Intrapatient treatment response heterogeneity is under-recognized. Quantitative total bone imaging (QTBI) using 18F-NaF positron emission tomography/computed tomography (PET/CT) scans is a tool that allows characterization of interlesional tr
Autor:
Neil H, White, Teresa, Quattrin, Lisa B St, Aubin, William T, Duggan, Richard D, England, Julie S, Fryburg
Publikováno v:
Journal of pediatric endocrinologymetabolism : JPEM. 21(6)
To compare the efficacy and safety of Exubera121 children were randomized to receive EXU or SC insulin, plus intermediate/ long-acting insulin for 12 weeks. Change in HbADecreases from baseline HbAThe efficacy and safety profiles shown in this study
Autor:
Gabriel P. Haas, Lawrence Karsh, William T. Duggan, Carl A. Olsson, Andrew J. Armstrong, Neeraj Agarwal, Raoul S. Concepcion, David F. Penson, Curtis Dunshee, Jennifer Sugg, Qi Shen, Celestia S. Higano
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:597-597
BACKGROUND In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and non